Purevax RCP
Active substance
ATC code
Species
Cats.
Indications
Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs,
- against feline panleucopenia to prevent mortality and clinical signs.
Onset of immunity: 1 week after primary vaccination course.
Duration of immunity: 1 year after the primary vaccination course and 3 years after the last re-vaccination.
Dose to be administered and administration route
Subcutaneous route.
Reconstitute gently the vaccine in order to obtain a uniform suspension with limited foam formation.
Visual appearance after reconstitution: clear slightly yellow suspension.
After reconstitution of the lyophilisate with 0.5 ml or 1 ml of the solvent (depending on the presentation chosen), inject one dose of vaccine according to the following vaccination schedule:
Primary vaccination course:
- first injection: from 8 weeks of age,
- second injection: 3 to 4 weeks later.
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9 to 12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
Revaccination:
- the first revaccination must be carried out one year after the primary vaccination course,
- subsequent revaccinations: at intervals of up to 3 years.
Adverse reactions
Cats:
|
Common (1 to 10 animals / 100 animals treated): |
Apathy, anorexia, and hyperthermia. 1 Injection site reactions (pain, itching, oedema).2 |
|
Uncommon (1 to 10 animals / 1 000 animals treated): |
Hypersensitivity reaction.3 |
|
Very rare (<1 animal / 10 000 animals treated, including isolated reports): |
Emesis.4 |
1 lasting usually for 1 or 2 days.
2 slight pain at palpation, itching or limited oedema disappearing within 1 or 2 weeks at most.
3 may require appropriate symptomatic treatment.
4 mostly within 24 to 48 hours.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder, or its local representative, or the national competent authority via the national reporting system. See also section “Contact details” of the package leaflet details.
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
TRUSTED SOURCE
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 04491/5053 |
| EAN | 4028691578123 |
